Mordin M, Fernandez M, Pearson I, Copley-Merriman K, McBride D. Similarities and differences in European HTA evidence requirements: one for all or one for none? Presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD.
Fernandez MM, Khan S, Mordin M, Copley-Merriman C, McBride D. Comparing literature review requirements for reimbursement submissions across the globe. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S108. doi: 10.1016/j.jval.2018.04.732
Copley-Merriman K. Value for money: health economics. Presented at the University of Michigan; October 29, 2015. Ann Arbor, MI.
Rycroft C, Fernandez M, Copley-Merriman K. Systematic literature reviews at the heart of health technology assessment: a comparison across markets. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A481.
Spinner DS, Birt J, Walter JW, Bowman L, Mauskopf J, Drummond MF, Copley-Merriman C. Do different clinical evidence bases lead to discordant health-technology assessment decisions? An in-depth case series across three jurisdictions. Clinicoecon Outcomes Res. 2013 Jan 1;5:69-85.
DeMuro C, Clark M, Mordin M, Fehnel S, Copley-Merriman C, Gnanasakthy A. Reasons for rejection of patient-reported outcome label claims: a compilation based on a review of patient-reported outcome use among new molecular entities and niologic license applications, 2006-2010. Value Health. 2012 May 1;15(3):443-8.
Gnanasakthy A, Mordin M, Clark M, DeMuro C, Fehnel S, Copley-Merriman C. A review of patient-reported outcome labels in the United States: 2006 to 2010. Value Health. 2012 May;15(3):437-42. doi: 10.1016/j.jval.2011.11.032
Walter JW, Spinner DS, Birt J, Bowman L, Mauskopf JA, Drummond M, Copley-Merriman K. Clinical and economic evidence bases for health technology assessment: a comparison of three jurisdictions. Poster presented at the 2011 ISPOR 14th Annual European Congress; November 2011. Madrid, Spain.
Nelson LM, Nixon A, Copley-Merriman K. Documenting PRO evidence for regulatory submissions to support labeling claims. Poster presented at the International Society for Quality of Life Research Workshop #2; October 2011.
Mauskopf J, Walter J, Birt J, Bowman L, Copley-Merriman C, Drummond M. Differences among formulary submission guidelines: implications for health technology assessment. Int J Technol Assess Health Care. 2011 Jul 1;27(3):261-70.
Mordin M, Clark M, DeMuro C, Evans ED, Copley-Merriman K, Fehnel S, Gnanasakthy A. Pro label claims: an analysis based on a review of pros among new molecular entities and biologic license applications 2006-2010. Poster presented at the 2011 ISPOR 16th Annual International Meeting; June 3, 2011. [abstract] Value Health. 2011 May; 14(3):A29.
DeMuro C, Mordin M, Evans ED, Copley-Merriman K, Fehnel S, Gnanasakthy A. Reasons for rejection of PRO label claims: an analysis based on a review of PRO use among new molecular entities and biologic license applications 2006–2010. Poster presented at the 2011 ISPOR 16th Annual International Meeting; June 3, 2011. [abstract] Value Health. 2011 May; 14(3):A29.
Norquist J, Nixon A, Copley-Merriman K. Documenting PRO evidence for EMA and FDA submissions to support promotional and labeling claims. Poster presented at the International Society for Quality of Life Research Workshop #12; October 2010.
Mordin MM, Lewis SA, Gnanasakthy A, DeMuro-Mercon CJ, Copley-Merriman K, Fehnel SE. Patient-reported outcomes in product development guidance. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 1, 2010. Atlanta, GA. [abstract] Value Health. 2010 May; 13(3):A-17-8.
Mordin M, Lewis SE, Gnanasakthy A, Demuro-Mercon C, Copley-Merriman K, Fehnel S. Patient-reported outcomes as mentioned in product development guidance. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 4, 2010. [abstract] Value Health. 2010 May; 13(3):A17-8.
Gnanasakthy A, DeMuro C, Mordin M, Copley-Merriman K, Mauskopf J. The role of the patient voice in health technology assessment. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 2010. Atlanta, GA. [abstract] Value Health. 2010 May; 13(3):A19. doi: 10.1016/S1098-3015(10)72074-X
Copley-Merriman K, Barrows SM, Whiteley J, Barrett AM. Value messages: developing, incorporating, and making use of a core strategic tool. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 28, 2009.
Copley-Merriman K, Barrett AM, Barrows SM, Whiteley J. Understanding and transmitting the value of a new drug. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research 14th Annual International Meeting; May 15, 2009.
Mordin MM, Clark M, Siersma CA, Copley-Merriman K, Gnanasakthy A. Impact of the FDA draft guidance on patient reported outcomes (PRO) label claims for approved drug products in the US: has it made a difference? Poster presented at the International Society for Pharmacoeconomics and Outcomes Research 14th Annual International Meeting; May 19, 2009. Orlando, FL. [abstract] Value Health. 2009 May; 12(3):A29.
Copley-Merriman C, Fehnel SE, Chandler J, Wild D. Obtaining a patient-reported outcomes label claim: what evidence do you need? Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 7, 2008.
Shah S, Sesti AM, Copley-Merriman K, Plante M. Quality of life terminology included in package inserts for US approved medications. Qual Life Res. 2003 Dec 1;12(8):1107-17.
Shah S, Sesti AM, Copley-Merriman K, Clark M. Summary of quality of life labeling components in the package inserts. Poster presented at the DIA-QOL Meeting; March 2002.
Santanello NC, Baker D, Cappelleri JC, Copley-Merriman K, DeMarinis R, Gagnon JP, Hsuan A, Jackson J, Mahmoud R, Miller D, Morgan M, Osterhaus J, Tilson H, Willke R. Regulatory issues for health-related quality of life—PhRMA Health Outcomes Committee Workshop, 1999. Value Health. 2002 Jan;5(1):14-25.
Shah S, Sesti AM, Chopra T, McLaughlin-Miley C, Copley-Merriman K. Quality of life terminology documented in package inserts. Mapi Quality of Life Newsletter. 2001 Jul;27:1-3.
Sesti A, Albright A, McLaughlin-Miley A, Copley-Merriman K. A methodology to measure productivity of health outcomes groups. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research; May 2000.
Wang A, Graham L, Copley-Merriman K. Treatment satisfaction in outcomes research: an overview of study measures. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research; May 2000.